About us

YUMAB is a biotechnology company founded in 2012 by experts and pioneers in recombinant antibody technologies of the University of Braunschweig, Germany. Since then, YUMAB has become a world leading provider for the development of fully human, therapeutic antibodies. YUMAB offers outstanding expertise from more than 30 years of continuous research in recombinant antibody technologies in combination with state of the art and next generation technologies. This unique setting enables novel solutions for current and future challenges in antibody immunotherapy.